The IO Switch: Making Tumor-Associated Macrophages Work In Our Favor
Executive Summary
Emerging Company Profile: Macrophage Pharma is using novel chemistry to deliver therapies directly into tumor-associated macrophages, switching their activity from immunosuppressive to immuno-stimulatory to initiate anti-tumor immune responses.
You may also be interested in...
Early Stage Science Watch
Scrip scans for early stage research – from bench to clinic – that could lead to novel treatments or changes in therapy recently published in major science journals.
Five Prime Enters Transition Phase; Multiple Trials Planned In Next 12 Months
Five Prime, in partnership with immunotherapy giant Bristol-Myers Squibb, will launch several pivotal trials in the next 12 months for its lead compound cabiralizumab – both in combination with Opdivo in cancer and as a monotherapy in orphan disease PVNS.
A Quick Primer On Roche's Immuno-Oncology Assets
Roche's broad cancer immunotherapy pipeline features a dozen novel agents, including the first candidates from new therapeutic platforms for bispecific antibodies and personalized cancer vaccines.